I don't think one can draw any inference as to the strength of MNTA's IP from its having lost a challenge to TEVA's Copaxone patents before court in the Southern District of New York. It was a test of TEVA's patents only.
MNTA's test should come in the fall in the trial of its suit against Amphastar/Watson for infringement of MNTA's patents. Given MNTA's home court advantage in the Ampha case, where the judge has already granted MNTA a preliminary injunction, I'd guess that MNTA's odds are much higher, and that we'll see a favorable view of their IP emerge from that trial. As I see it, the recent modest run up in the MNTA stock price was a reasonable gamble that they'd win the New York case. I would think that its price should stay in the 13s for the next several months before starting to creep up in a similar manner as the Ampha verdict date approaches.
OT, but I'm looking forward to seeing what the SCOTUS does with Obamacare today....
Market Data 
Markets 
AI
